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Immune checkpoint inhibition represents a promising approach for multiple 
malignancies. Why successful T cell responses are achieved in only some patients is not 
well understood. We investigated how combined loss of PD-1 and LAG-3 signaling in 
CD8+ T cells would influence a well-characterized immune response. After challenge with 
recombinant vaccinia virus expressing ovalbumin (VV-OVA), T cells from mice lacking 
both inhibitory pathways underwent a more vigorous primary effector cell response but 
were severely defective during a secondary challenge. Mechanistically, combined immune 
checkpoint inhibition resulted in greater production of irreversibly differentiated effector 
cell progeny, but at the expense of self-renewal of progenitor cells. Drugs that blunt 
anabolism-associated signaling corrected progenitor cell loss driven by combined 
checkpoint inhibition. Unleashing greater T cell activation may accelerate regenerative 
failure of critical clones. Fostering expansion of self-renewing progenitors using reversible 
agents that dampen T cell signal strength might paradoxically improve, not impede, the 
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Chapter I: Introduction 
Section 1.1: Immune curiosity, the vaccine that conquers ‘Rose buds'* 
 
The first notions of immunological memory 
"Yet it was with those who had recovered from the disease that the sick and 
the dying found most compassion. These knew what it was from experience, and had now 
no fear for themselves; for the same man was never attacked twice" Thucydides (ca. 430 
BCE).1  
 
History tells us that ancient civilizations had recognized notions of disease. As early as 
2000 BCE the Babylonian epic of Gilgamesh is not only the first written down literary 
work, but it narrates the existence of disease and pestilence.2,3 Humans undoubtably are 
curious and since early times were observant and questioned about why disease could kill 
some while others survived. The curiosity for the concept of immunologic memory has 
been in the human mind through time and space. In the ancient Greece, the historian 
Thucydides registers that survivors of the plague did not get infected a second time.4  The 
notion of “immunity” is first registered in the works of non-physician Greeks and  in the 
same way the concept of immunity is used in the frame of disease first in Roma with 
those who had no training or practiced medicine.  
 
 
                                                          
* Reference to ‘Upon the death of the Lord Hastings,’ poem by John Dryden upon the death by smallpox 
of his schoolmate and friend Lord Hastings.249 
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The first registered use of the word immune in the human history, appears in Rome in the 
Histories by Polybious (200-117 BCE). In Latin immunitas and immunis originate from 
the legal concept of exception from a service or a duty.5 It is until around 60 CE that 
immunitas is used to refer as exemption from disease, from lethal poison. Marcus 
Annaeus Lucanus in his poem Pharsalia describes the resistance to snake venom: “ The 
nature of the country has arranged that, because living mixed with snakes, they are 
immune to them.”6 
 
The Chinese were the ones that not only observed but preformed the earliest attempt to 
immunize. They approach the treatment of smallpox through variolation.7  The technique 
acquired popularity in the Ottoman Empire and from there it spread in Europe thanks to 
adventuress Lady Mary Worley Montagu .8,9  Variolation helped to prevent smallpox. 
However, it was still unclear at that time how and why this “phenomena” was caused.  
 
The unknown and limited control over variolation made of the technique a game of 
randomness.  Of those variolated 1% to 2% died, which was still a gain considering that 
those who died after smallpox infection were 30%. 8,10 The idea behind variolation as a 
means to fight smallpox was used later in England by Jenner (1796 CE).11  He was the 






The idea of an acquired protection is long lived; however, the concept of immunological 
memory although pivotal for the study of the immune system, is relative recent. The 
scientific literature has recorded it as such during the 50’s and 60’s.13,14 Immunological 
memory is one of the key concepts in the study of contemporary immunology.15 How we 
define immunological memory continue to evolve and expand as we gain more 




















Section 1.2: CD8+ T cells 
 
CD8+ T cell activation and effector function 
CD8+ T cells play a key role in the adaptive immune response to pathogens and 
cancer.18,19 The precursors of T cells arise in the bone marrow and migrate to the thymus. 
Naïve CD8+ T cells are generated in the thymus where they mature from hematopoietic 
stem cell (HSC) precursors.20,21 After thymic selection, naïve CD8+ T cells travel and 
seed in peripheral lymphoid tissue sites.22 In the periphery and out of the thymus, naïve 
CD8+ T cells are maintained through IL-7 and low-level tonic T cell receptor (TCR) 
signaling.23  
 
Under pathogenic infection, naïve CD8+ t cells can recognize foreign epitopes however, 
their initial frequency is low.24 In the mouse for example, naïve CD8+ T cells range 
between 10 and 3000 antigen-specific T cells per mouse.25 CD8+ T cells can expand to 
104 to 105 in a period of 8 days.24 All of this happens in specialized lymphoid organs 
where naïve CD8+ T cells are recruited and seeded. It is crucial for CD8+ T cells to 
rapidly expand, travel to the compromised sites and fight infection.18,26,27  
 
There is a highly diverse repertoire of TCR in the naïve CD8+ T cells pool. The TCR 
needs to engage with a cognate antigen in order to be activated. But TCR recognition is 
not enough. Once naïve CD8+ T cells are stimulated by antigen presenting cells, they 
receive co-stimulation and interact with pro-inflammatory cytokines,  they expand and 
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respond to infection (Fig. 1.1).28–30 CD8+ naïve T cells undergo considerable changes in 








































Figure 1.1 Priming of a CD8+ T cell.  CD8+ T cells are a pivotal part of the adaptative 
immune system. After pathogen encounter, naïve T cells differentiate into effector T cells 
with specialized functions that help to clear invading pathogens. For full naïve CD8+ T 
cell activation the following four steps are necessary: 1. the engagement of TCR; 2. the 
recognition of cognate antigen under MHC I context in APC; 3. the engagement of 
immune checkpoint receptor and ligand; and 4. the interaction with inflammatory 
cytokines. If this interaction occurs the result is rapid proliferation and differentiation into 


















CD8+ T cells expand and whether or not they successfully eliminate pathogen infection, 
they return to homeostasis and undergo a rapid systemic reduction during the contraction 
phase (Fig. 1.2).33,34 Some studies already have pointed to the fact that T cells are 
programmed or primed to be memory cells during the very stages of the priming phase.35 
It has been reported that activation and early expansion stages are crucial to determine the 
fate of CD8+ T cells.36 In our studies we use recombinant vaccinia virus expressing 
ovalbumin peptide epitope which is fully immunogenic and elicits a strong CD8+ 
response37,38 Vaccinia virus (VV) has been an important tool to study poxivirus infection. 























































Figure 1.2 Kinetics of CD8+ T cell expansion during primary acute response.  T cell 
differentiation during an acute response. (A) Kinetic curve of T cell expansion during a 
viral infection. (B) After pathogen encounter CD8+ T cells expand once pathogen is 
cleared, most of those clones die and the population contracts until just few clones 

















Another important aspect in the study of CD8+ T cells is the extensive metabolic changes 
that happen during activation and memory formation. CD8+ T cells that differentiate into 
effector cells undergo several changes, in shape and function and metabolic reprograming 
from mitochondrial oxidative phosphorylation (OXPHOS) to glycolysis.42   
 
Numerous studies have reported different metabolic programs during asymmetric CD8+ T 
cell division in the context of infection response. Once naïve CD8+ T cells are activated 
they give rise to a daughter and a progenitor cells with opposite metabolic pathways. 
Naïve and memory cells show a catabolic program while CD8+ T cells that become 
effector adopt an anabolic metabolism program. 43–51 
 
Needless to say, during this metabolic changes CD8+ T cells adopt different signaling 
programs that affect the outcome of their functions. TCF1 is an important transcription 
factor that determines the fate of a CD8+ T cell becoming a memory cell.52,53  
 
Several aspects of CD8+ T cells have been elucidated, however it is still unknown how 
they form memory. An important motivation to keep deciphering CD8+ T cells memory 
formation is the design of vaccines. As mentioned in section one, vaccines that stimulate 
strongly the production of antibodies have been successful. However, such vaccines are 





There is an undeniable progress in the study of CD8+ T cells. It is important to focus in 
elucidating the factors that direct CD8+ T cell differentiation that can help modulate and 
manipulate the outcomes of CD8+ T cell priming. Molecular engineering and 
pharmacological tools can be used to control CD8+ T cell responses that can be of 
promising use in the clinic and the development of several therapies including but not 

















Section 1.3: The making of immunological memories 
 
Immunological memory: an attempt at conceptualization. 
As the wild man Endiku helped the great king to learn humility,2 history and perspective 
have helped scientist to be humble and to understand how complex the immune system 
can be. For several years the advancement of what is known as cellular immunology had 
a slow progress, as Arnold Rich pointed out in 1953 “Literally nothing of importance is 
known regarding the potentialities of [small lymphocytes], which constituted, “one of the 
most humiliating and disgraceful gaps in all medical knowledge.”54 It has taken a long 
time and effort to elucidate what we so far know about immunological memory and CD8+ 
T cells. 
 
Immunological memory is a unique characteristic of the immune system. Under a 
classical view, immunological memory is the acquisition of long-term acquired 
protection through vaccination or infection.55,56 With a more complex understanding, 
immunological memory concedes the ability to respond in a faster and more efficient way 
to the second invasion of a pathogen and constitutes the basis for vaccination.17  
 
But what is behind a successful vaccine and the maintenance of immune memory?  
We have some effective vaccines that have helped eliminate or minimize the 
consequences of some mortal and disability causing diseases. The smallpox vaccine was 
the first vaccine to be used worldwide in humans with great success that in 1979 
smallpox was eradicated.57 To date only smallpox and rinderpest have been 
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eradicated.58,59 Without doubt vaccines are one of the greatest medicine achievements. 
The most effective vaccines nowadays are the ones that stimulate the generation of 
antibodies.60 However, there are still diseases that are a challenge for protective vaccines. 
Among such diseases are Malaria, HIV and Tuberculosis for example, that are resistant to 
humoral immunity.61–63 Thus, to target those diseases it is necessary to generate vaccines 
that aim towards the stimulation of cellular immunity like CD8+ T cells. Such vaccines 
have proven a major challenge.63 CD8+ T cell vaccine generation is important because of 
their specificity to proteins and for granting sterilizing immunity.64–66 CD8+ T cells are 
important in the vaccine design; they control intracellular pathogens and also are able to 
limit tumor establishment and growth.67,68 CD8+ T cells can also be autoreactive and 
attack self.69,70  Therefore, vaccines can also fight cancer and autoimmune diseases and 
are currently a very active area of research.17,71–74 
 
The understanding of immunology and that of immunological memory did not emerge in 
an orderly form. It also has been slow and challenging to emerge. Discerning the 
conceptual aspects of immunological memory is still a work in progress, and the 
mechanisms underlying its formation and orchestration are still evolving. A clear 
example is the challenging of notion that immunological memory is only limited to B and 
T cells, when in fact evidence points that exits in a wide set of diverse immune cells like 






For long the immune system was thought to be a harmless mechanism that protected 
against external pathogens. But in early 1902 a seminal work by Porter and Richet† report 
an aberrant behavior or the immune system: “anaphylaxis.”80  This important report helps 
to approach the understanding of immunization with a new perspective. Immunization 
was not anymore, a way to protect against a pathogen, it was also an event with the 
capability of causing harmful events and sever disease. Thus, the immune system revels a 
dark side showing that can harm the host instead of only protecting it. This helps to focus 














                                                          
† The thesis author opposes the views of Richet on psychic phenomena or withe supremacy, although his 
unrelated studies on anaphylaxis are important. The author however would like to point out the 
importance of Porter in the anaphylaxis studies made with Richet. Porter was a great scientist but 
forgotten for his humility in declining the Nobel price.  
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Section 1.4: Creating new memories 
 
Immunology is a science that has a wide array of different concepts, definitions and 
theories. Several of such concepts are only familiar to immunologists, like “suppressor 
cells;” and other concepts that are used by non-immunologists such as “monoclonal 
antibodies.”85 All these concepts emerged to answer questions and to satisfy curiosities. 
In immunology the understanding and elucidation of some concepts has made slow 
progress and not without controversies. One example is the case of the understanding of 
cellular immunology. 86 In fact one of the longest battles in immunology, has to do with 
humoral vs cellular immunology.87  
 
Parallel to satisfying the curiosity around immunity, new doubts have emerged. 
Nowadays a controversial topic in the immunology field surrounds immunological 
memory.  For example the understanding of how T cell memory is successfully generated 
is a current and active field of research.16 CD8+ T cells play a pivotal role in cellular 
immunology, and their study is important for vaccine design.88 
 
Although studies have described how T cell memory is generated following acute 
infection, less is known about the maintenance of T cell memory in the context of 





The formation of CD8+ T cell memory is an active research topic, understanding how it 
happens can help towards the design of effective vaccines.  Understanding how CD8+ T 
cells go from naïve to effector to memory and orchestrate metabolic changes that 
influence and imprint their future behavior as memory cells.73  
 
CD8+ T cell memory 
After pathogen clearance, some effector T cells that responded to infection persist and 
become memory T cells.27 There are several proposed models as how CD8+ T cell 
memory is formed.15,16,36,89,90  In our studies we make use of parameters proposed for 
different  memory models. It has been proposed that a small fraction of effector CD8+ T 
cells survive the contraction phase and are identified as memory precursor effector cells 
(MPECs) and can be distinguished because of their high expression levels of CD127 and 
decreased expression of KLRG receptor. The other dominant population of effector CD8+ 
T cells has high expression of KLRG1 and low expression of CD127 and it has been 
identified as short-lived effector cells (SLECs).91–95  These two populations have been 
observed in different infectious contexts in mouse and human, however the presence of 
MPECs and SLECs is not the only criterion for identifying memory precursors after an 
immune response; nor are they universally required for the formation of CD8+ T cell 
memory.96–98  
 
The “asymmetric cell fate” models shows that a single precursor T cell can yield both an 
effector and a memory T cell through asymmetric division.52,99–102 In our studies we work 




Other models propose the influence of other factors in the fate of a CD8+ T cell, for 
example TCR signaling strength that has been negatively associated with memory 
formation.103,104 Additionally, the transcription factor profile becomes distinctive for T 
cells that become effectors when compared to T cells that become memory. IRF4 for 
example has been shown to be important in the formation and expansion of effector 
cells.105 Other crucial transcription factors reported for CD8+ memory formation are 
Eomes and TCF1.106,107 
 
Additionally, TCF1 is also highly expressed in naïve CD8+ T cells, promoting self-
renewal. TCF1 is downregulated in effector cells and is expressed again in memory cells. 














Section 1.5: CD8+ T cells in the tumor microenvironment 
 
Immunotherapy 
Our curiosity of how the immune system works has not been satisfied; new concepts and 
questions emerge the more we learn. But we not only want to learn more about the 
functioning of the immune system but also how to use it and hack it to our benefit. For 
example, with immunotherapy, in specific cancer immune checkpoint therapy. 
 
Nowadays the idea that the immune system plays a pivotal role in conferring protection 
against cancer is well established. The first concept of immunotherapy can be attributed 
to Dr. William Coley’s efforts in 1893 to treat tumors through a local injection of “ 
Coley’s Toxins,” a mixture of live bacteria used as an immune stimulant.109,110   
 
By 1890 there was already the concept of immune surveillance that was proposed by 
Ehrlich: a scanning of the human body the immune system to eradicate transformed cells. 
111 At the beginning of the 20th century the notion of “immunosurveillance” of cancer was 
proposed. Similarly, by the early decade of the 70’s Burnet and Prehm brought back the 
concept of tumor immunosurveillance. They purposed that tumors were eliminated by the 


























Figure 1.3 Immune checkpoints. Immune checkpoints contribute to regulate the 
amplitude and quality of T cell responses. Immune checkpoints can stimulate a CD8+ T 
cell response namely CD28 or can inhibit responses. Programmed cell death 1 (PD-1) and 
lymphocyte-activation gene 3 (LAG-3) are inhibitory immune checkpoints that contribute 





















But why immune checkpoint therapy?  
Immune responses are potent and need to be tightly regulated to avoid unnecessary or 
unwanted responses that could result in tissue damage and the break of self-tolerance.114–
116 Immune checkpoints are a wide array of molecules expressed in the surface of cells 
that function as co-receptors that either promote or inhibit T-cell activation (Fig.1.3).117 
During T cell activation inhibitory receptors are up regulated as well as stimulatory ones. 
This is a way to regulate overstimulation of the immune cells responding to an infection 
after pathogen encounter.118 Kummel and Allison described the immune checkpoint 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)’s ability to inhibit T cell 
responses and how using a blocking antibody against CTLA-4 could promote T cell 
mediated tumor rejection.119 Several studies followed and immune checkpoints have been 
the focus of research since, their understanding and elucidation has contributed to the 
development of blocking antibody based therapies that restore CD8+ T cell function and 
tumor immunity.109  
 
Tumor infiltrating CD8+ T cells’ functions can be modulated by using antibodies that 
target immune check points that either stimulate or inhibit cell functions.120  This 








Immune check points 
Immune checkpoints contribute to regulate the amplitude and quality of T cell responses 
and have been a major focus of study to enhance current immune therapies.123 
Programmed cell death 1 (PD-1) and lymphocyte-activation gene 3 (LAG-3) are immune 
checkpoints that contribute to T cell homeostasis, activation and differentiation.89,124–128 
Previous studies in murine tumor models report enhanced T cell function in the absence 
of PD-1 and LAG-3 as a result of the synergy between these inhibitory pathways.129  The 
effect of combined loss of PD-1 and LAG-3 on the formation of long-term CD8+ T cell 
memory, however, has not been evaluated.   
 
PD-1 
Immunotherapy for cancer is currently used with efficacy and promising results in the 
clinic. However more studies are needed since not all patients benefit from PD-1 
therapy.130 A common way to therapeutically target PD-1 in the clinic is through the use 
of antibody blockade of PD-1/PDL-1 to disrupt the ligand/ligand interaction.131 
 
PD-1 was cloned in 1992; it was first identified as a type I transmembrane protein.132 
Currently it is known as an immunoreceptor tyrosine-based switch motive (ITSM) 
containing inhibitory molecule.124 PD-1 is a member of the B7 family of co-
stimulatory/co-inhibitory receptors and after initial immune stimulus is transiently 
expressed in  several immune cells: CD4+ and CD8+ T cells, B cells and natural killer 
(NK) cells, macrophages, dendritic cells and some cancer cells.67,133–140 It has two known 
ligands: PDL-1that is expressed ubiquitously and PDL-2 that has restricted expression 
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when compared to PDL-1, in that is expressed in APC  and macrophages.128 PDL-1- has 
been reported to be expressed in some tumor environments.141  
 
PD-1/PDL-1 interactions are antagonists of CD80/CD28 co-stimulation such interaction 
results in diminished to cytokine production, cell arrest and stops production of  the pro-
survival Bcl-X.142,143  PD-1 strongly interferes with TCR signal transduction, even at low 
expression, by recruiting Src homology region 2 domain-containing phosphatase-1 
(SHP1)  and protein-tyrosine phosphatase 1D (SHP2) that interfere with the CD28 
phosphorylation and interaction with TCR.124   
 
PD-1 mediates central and peripheral immune tolerance in addition of immune 
exhaustion.144–147  PD-1 has been reported to potentially help metabolic reprograming of 
T cells from effector to long-lived memory cells. This is seen by the shift from high 
glycolysis towards fatty acid B-oxidation.46,148  
 
PD-1 is also a maker of exhausted T cells.149 High expression of PD-1 has been linked to 
cell exhaustion in chronic viral infections.150  When a CD8+ T cell is exhausted, it 
becomes faulty in secreting cytokines, it stops proliferating and is unable to accomplish 
tolerance related functions.151–153 Tumor infiltrating T cells have a high expression of PD-
1 in some tumor microenvironments and PDL-1 signaling is how tumors can avoid 
destruction by cells expressing PD-1 like CD-8+ T cells for example.122,154–158 Through 
the blocking of PD-1 signaling anti-tumor response can be achieved.159,160 The tumor 
microenvironment is potentially hosting several immune cells like PD1+ T cells that are 
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antigen experienced but are exhausted or inactivated by the tumor microenvironment. 
161,162 The molecular elucidation of how PD-1 blockade therapy works has not been 
reported yet. However, it is a promising hope for the treatment of cancer. 
 
LAG-3 
Lymphocyte activation gene 3 (LAG-3) is also a co-inhibitory immune checkpoint that 
plays an important role in T-cell tolerance and T cell modulation, impeding endogenous 
unnecessary immune responses in non-aberrant physiological conditions.163,164 As in 
several other checkpoints, LAG-3 is highly expressed in the tumor microenvironment 
giving advantage to the tumor and allowing evasion of anti-tumor immunity.165 
 
LAG-3 was cloned in 1990 and it was identified as a membrane protein.166 Structurally 
LAG-3 is similar to the CD4+ molecule.  It is considered an activation marker for CD4+ 
and CD8+ T cells and it is also expressed on NK cells, B cells, Tregs and DCs.129,167  
LAG-3 expression is transient and short lived at the protein level in the early stages of T 
cell activation. LAG-3 is highly expressed by T-regs mostly at the mRNA level compared 
to the protein level.168 Studies have shown that the primary function of LAG-3 is to 
inhibit T cell expansion as well as to control the size of the memory T cell pool.89 
Additionally it regulates T cell homeostasis and plays a key role enhancing the functions 
of regulatory T cells.169 LAG-3 has been shown to interact with MHC-II with higher 
affinity than CD4+ T cells.163,170 Therapeutically, blocking the interaction of LAG-3 and 
MHC-I expressed by APC has shown an increase of infiltrating CD8+ T cells in the tumor 




Studies have reported that LAG-3 potentially associated with TCR/CD3 complexes on T 
cells results in a crosslinking that stops the calcium response to CD3 stimulation.172 How 
the downstream signaling works is still being elucidated. Exhausted CD8+ T cells have 
also been reported to highly express LAG-3 conjointly with PD-1. 154 LAG-3 KO mice 
do not however, develop spontaneous lymphoproliferative disease. Such mice live for 
about a year and develop dermatitis and die usually of hard to cure skin infections.  In the 
clinic antibody against LAG-3 binds to tumor infiltrating CD8+ T cells and helps reduce 
tumor burden by activating antigen specific T cells.173 
 
  
PD-1 and LAG-3 in CD8+ memory formation. 
But why the interest in the formation of CD8+ T cell memory in the context of inhibitory 
receptors? Several studies have shown the importance of the PD-1 and LAG-3 receptors 
in regulating T cell activation and function in a synergistic manner in mouse tumor 
models.129,174 Furthermore, it has been reported that there is a reduction of tumor burden 
in the absence of PD-1 and LAG-3.129 However, other work has shown that loss of PD-1 
signaling in T cells in a chronic infection model contributes to an exhausted-like state for 
memory cells. Studies show that the absence of LAG-3 in T cells increases clonotypic 
expansion and effector function in a tumor model.126 
 
The combined effect of the loss of PD-1 and LAG-3 on the formation of long-term 
memory has not been described. Combinatorial immunotherapies have proven to be a 
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powerful approach to treat cancer. Immunotherapy directed toward PD-1 and LAG-3 has 
shown promising results in multiple trials. Understanding how PD-1 and LAG-3 interact 
will help to improve current therapies to reduce tumor burden and also contribute to the 
development of durable and preventive therapies.  One of the main goals of 
immunotherapy is to develop lasting immunity to cancer that can reduce recurrence. 
Understanding the formation of long-term T cell memory in the context of immune 



















CHAPTER II: METHODS 
 
Mice and infections 
All mice were housed and used in accordance with the guidelines of the Johns Hopkins 
University Institutional Animal Care and Use Committee under an approved protocol. 
CD45.1 mice were purchased from Charles River. OT-1 mice were originally obtained 
from Dr. M. Bevan (University of Washington), and bred onto a RAG2 -/- background at 
JHU prior to use. PD-1 KO mice on a C57/B6 background were provided by Dr. 
Lienping Chen (Yale University) with permission from Dr. T. Honjo (Kyoto University). 
LAG-3 KO mice on a C57BL/6 background were provided by Dr. Yueh-Hsiu Chien 
(Stanford University, CA) with permission from Dr. Christophe Benoist and Dr. Diane 
Mathis (Joslin Diabetes Center, Boston, MA).  
 
P14 TCR transgenic mice recognizing LCMV peptide gp33-41/H2Db were purchased 
from The Jackson Laboratory (Bar Harbor, ME). For experiments modeling the acute 
response to primary infection, mice were infected with 106  plaque-forming units (PFUs) 
of Vaccinia-OVA (VV-OVA) or 107 colony-forming units (CFU) of Listeria-ova (LM-
OVA). For re-challenge experiments assessing recall responses, mice were first infected 
with VV-OVA and subsequently re-challenged at day 60 post primary infection with 107 
CFU attenuated Listeria, a gift of Dr. Pete Lauer (Aduro Biotech). VV-OVA was gift 
from Dr. Drew Pardoll, it was originally generated by Dr. Nick Restifo by homologous 
recombination into the WR strain of Vaccinia. It encodes full length ovalbumin.  To 
generate acutely infections in P14 mice we used 2x105 PFU of LCMV, Armstrong strain. 
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Adoptive Transfer and lymphocyte isolation 
CD8+ T-cells isolated from the spleen and peripheral lymph nodes of 4 - 6-week-old OT-
1 RAG2 KO mice. CD8+ T cells were enriched from the spleen using Naive CD8+ T cell 
positive isolation kit (Miltenyi), according to manufacturer’s protocol. 5x10^5 CD8+ T 
cells were then administered by tail vein injection into congenically distinct recipient 
mice (C57/B6 CD45.1) one day prior to infection with VV-OVA.  At day 8 p.i. Spleens, 
livers, lungs and LN were harvested at day 8 post infection (p.i.) for the primary infection 
and at day 64 for secondary infection. The phenotype of adoptively transferred cells was 
determined by flow cytometry. Same procedures were followed for PD-1 KO, LAG-3 
KO, DKO CD8+ OT-1 and P14 T-cells isolation. To assess maintenance and/or rejection 
of transferred cells, organs were harvested at day 21 p.i (Fig 2.1). 
 
In vitro stimulation and TCF1 staining 
To model the process whereby TCF1hi activated CD8+ T cell progenitors of a defined 
specificity give rise to irreversibly determined TCF1lo effector cells while self-renewing 
TCF1hi progenitors, as evident during acute infection.52 TCR transgenic T cells were 
activated in vitro.43,52,175  
 
Whole spleens from OT-1 RAG2 KO mice and P14 mice were processed as described 
previously,125 they were labeled with cell proliferation dye (CTV), and incubated and 
stimulated with peptide SIINFEKL or LCMV gp33 peptide KAVYNFATM for 4 days in 
RPMI complete media. Some groups received 50 ug/mL of either αPD-1 (clone J43) 
and/or αLAG-3 (clone C9B7W), or rat IgG1 and Armenian Hamster IgG isotype control 
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antibody (Bioxcell, West Lebanon, NH). Some groups were treated with N-acetyl 
cysteine (Sigma, 7mM) or Pictilisib (Class I PI3K inhibitor, Selleckchem, 1μM). In day 4 
of incubation cells were collected and stained for TCF1 as previously described.176 
 
Flow cytometry 
To discriminate live from dead cells, all cells were stained with LIVE/DEAD Fixable Dead 
Cell Stain (Life Technologies). Surface staining was performed as described previously125. 
Anti- CD8+α (5H10) was purchased from Invitrogen. The following antibodies were 
purchased from Biolegend: CD45.2 (104), IFNγ (XMG1.2). LAG-3 (C9B7W), TNFα 
(MP6-XT22), Granzyme B PD-1 (J43), T-bet (ebio4B10), were purchased from 
Ebioscience. All antibodies were used according to manufacturer’s protocol. Intracellular 
cytokine staining was performed following a 5 hour incubation at 37°C in 5% CO2 in 
complete media supplemented with the 50μM of OVA-SIINFEKL and protein transport 
inhibitor (Ebioscience). Cells were then fixed and stained using Cytofix/Cytoperm kit (BD) 
according to the manufacturer's instructions. Flow cytometry was performed on a 
FACsCalibur or LSR II (BD, San Diego, CA), and analyzed using FlowJo software (Tree 
Star). For intracellular staining of transcription factors, a FoxP3 staining kit (eBioscience) 
was used according to the manufacturer’s instructions. 
 
Data Analysis and Statistics 
All data were generated using FlowJo software (Treestar), Graphpad Prism software, 



















Fig 2.1. Mouse models and adoptive transfer schema. Graphical description of the two 
types of conditions used with OT-I mice. CD8+ T cells were isolated from a CD41.2 
donor mouse and adoptively transferred to a CD45.1 host mouse. (A) In one condition, 
the mice either received blocking antibody and the spleen and blood where collected to 
read their phenotype in the flocytometer. (B) Cells with different knocked out molecules 
were used in stead of the blocking antibody and the spleen, liver, lymph nodes and lungs 




































Chapter III: Expansion/kinetics 
 
Section 3.1: Introduction 
 
After the exposure to a foreign antigen through either infection or vaccination, the 
immune system elicits a strong response to protect the host.177 During the acute phase of 
infection cells need to be primed, expand, become effectors, traffic to sites of infection 
and carry out pathogen clearance.18  CD8+ T cells, one of the main mediators of the 
adaptative immune response, are one of the key players of the adaptive immune 
system.178 Their activation is necessary for the control of pathogen invasion.90 One of the 
primary goals of CD8+ T cell response to infection is to generate large numbers or clones 
to help eliminate infection.179 
 
It is estimated that there is 1 naïve CD8+ T cell in 10,000, specific for any particular 
antigen.24 Once activated a naïve CD8+ T cell can dramatically expand to 50,000 fold.180 
Because of such dramatic expansion and a powerful response of the immune system there 
are several mechanisms in place to prevent immune reactions to self-proteins.181 A naïve 
CD8+ T cell must receive 3 signals to engage in an immune response: the recognition of 
peptide in the context of MHC class I, signaling through the engagement of costimulatory 
receptors and cytokine signaling.29,182,183 
 
There are several factors that enhance the magnitude of the immune response: frequency 
of naïve CD8+ T cells, number of naïve CD8+ T cells recruited to site of infection, 
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duration and quality of infection, immunodominance and peptide affinity for example.184–
186  But what exactly directs the size of the clonal pool of CD8+ T cells has been 
determined with precision to be the precursor frequency of naïve CD8+ T cells for a 
specific antigen. In other words, the number of CD8+ T cell specific for an antigen before 
infection, is  the critical parameter defining the magnitude of expansion.187,188  
 
Naïve CD8+T cells scan between 160 and 300 dendritic cells per hour and stay in a lymph 
node for about half a day to a day.189 When a naïve CD8+ T cell encounters a dendritic 
cell with a  cognate antigen, they stay in contact for about a day during which they 
“blast.”190–193 Short exposure to cognate antigen - as little as 2 hours- is enough to drive a 
naïve CD8+ T cell  to several rounds of division in vitro.194,195 However in vivo a period 
of 20 hours is necessary to fully activate a naïve CD8+ T cell that afterwards can 
differentiate into effector cells and later into memory cells35,47,195–197 
 
In the next several hours to days after exposure CD8+ T cells enter a profound change: 
their interaction with dendritic cells causes them to increase in size by doubling their 
protein production and content, they change their metabolism and increase their RNA 
content  about 30 fold to 1,300 mRNAs.42,46,198,199  Naïve CD8+ T cells leave their 
inactive resting state and become metabolically dependent on glucose to satisfy their need 
for rapid proliferation and biosynthesis to ensure growth and differentiation.46 All of 




During the acute phase of our studies we use VV-OVA that causes proliferation of OT-I 
cells initially in the lymph nodes and spleens.38 CD8+ T cells respond to VV-OVA by 
dividing and inducing cytolytic activity and production of IFN-, and TNF-.200,201 Once 
naïve CD8+ T cells are primed they expand and reach a peak at about 7 to 10 days after 
infection; the exact day of peaking is pathogen dependent.18,26,36,202 Once peak of 
expansion is reached, the proliferative potential of the differentiated CD8+ T cells 
declines and they die by apoptosis.29  
 
The rapid proliferation and expansion of immune cells during an immune response is so 
powerful that to inhibit, modulate and control unwanted responses the immune system 
has in place several tightly regulated mechanisms .203,204  Inhibitory receptors are in part 
responsible for regulating uncontrolled or unwanted expansion of activated T cells.205,206 
T cells express counterparts of stimulatory molecules known as inhibitory check points. 
They help to modulate the T cell response to pathogen infection.115  
 
The co-inhibitory receptor LAG-3, has been reported to regulate T-cell function and to 
control effector T-cell expansion and homeostasis.89,127,168Adittionally, other studies show 
that PD-1 and LAG-3 inhibitory co-receptors act synergistically207, and both enhance 
CD8+ T cell clonal expansion,129 as observed in tumor bearing mouse models and 





In our studies we outline the kinetics of CD8+ T cell immune response in the absence of 
PD-1 and LAG-3 during the primary response to acute infection of VV-OVA. Previous 
studies have reported that in the spleen CD8+ response to VV-OVA is comparable to that 






















Section 3.2: Results 
 
Loss of PD-1 and LAG-3 increases effector cell expansion in the peripheral blood during 
primary acute infection of VV-OVA. 
To determine the role of the inhibitory receptors PD-1 and LAG-3 in CD8+ T cell 
differentiation, we used an OT-I PD-1/LAG-3 double KO mouse model. After 
immunization with VV-OVA, CD8+ T cells are considerably increased in number in 
circulating blood in the spleen. We also observed increased number in the liver, lymph 
nodes and lung. We first examined the early expansion of CD8+ T cells by assessing their 
presence in circulating blood (Fig. 3.1B). In the absence of PD-1 and LAG-3, CD8+ T 
cells had proliferative advantage; their presence in the circulating blood was noticeable 
earlier than the wild type (WT) group. The absence of both inhibitory receptors results in 
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Figure 3.1 Absence of PD-1 and LAG-3 influences CD8+ T cell expansion. (A) 
Schematic representation of blood collection to check clonal expansion of adoptively 
transferred CD8+ T cells. Blood was collected daily from the tail. (B) Kinetic curve of 
CD8+ T cell expansion showing in red the early and wider clonal of cells with double 




















Loss of PD-1 and LAG-3 enhances effector cell expansion in lymphatic and systemic 
organs during primary acute infection of VV-OVA. 
Once we learned that in the absence of PD-1 and LAG-3 CD8+ T cells expanded during 
the early days of primary phase of the acute infection, we investigated the proliferating 
capacity of OT-I CD8+ T cells during the acute response in the systemic and lymphoid 
organs at the peak of the expansion. We sought to test the hypothesis that in a murine 
tumor-free model the absence of PD-1 and LAG3 influences cell expansion. At day 8 
post infection (p.i.) mice organs were collected (spleen, liver, lymph nodes and lung), and 
when compared to WT, PD-1 KO and LAG-3 KO double knock out (DKO) CD8+ T cells 
(PD-1 KO/LAG-3 KO) have greater expansion as shown by the presence of a greater 
percent and absolute number of cells in the spleen, liver, lung and lymph nodes when 




































































Figure 3.2 PD-1/LAG-3 absence influences CD8+ T cell expansion in the acute phase 
of infection. (A) Schematic representation of organ collection. (B - E) Frequency and 
absolute numbers of transferred WT, PD-1 KO, LAG-3 KO and DKO T cells in spleen, 
liver, lymph node and lungs at day 8 p.i. N = 5 mice / group. Experiments were repeated 





















Section 3.3: Discussion 
 
For an effective response to infection, effector CD8+ T cells need to expand and respond 
to the invading pathogen. CD8+ T cells acquire cytolytic functions and secrete cytokines. 
The first step during the response to infection, is the recognition of cognate antigen by 
CD8+ T cells; in our studies we use vaccinia ova engineered to express ova peptide.  
When CD8+ T cells respond to infection, they need to pass through an initial activation 
and an expansion phase. Virus-specific CD8+ T cells, in our studies OT-I, respond to viral 
infection by sustaining several rounds of cell division that results in clonal expansion.  
 
Vaccinia virus generates immunity through the interaction of dendritic cells that are the 
best activators of CD8+ T cells.209  Transferred OT-I cells first proliferate in response to 
antigen in the spleens and draining lymph nodes; after day 2 several rounds of division 
have already happened.38 Previous experiments using murine tumor models have shown 
that in the absence of PD-1 and LAG-3, CD8+ T cells increase in number and effector 
function.129 Here we observe the expansion of CD8+ T cells in the absence of PD-1 and 
LAG-3 in tumor and autoimmunity free mice during an acute infection with vaccinia-ova. 
We sought to test the hypothesis that in a murine tumor-free model the absence of PD-1 






First, we tested the ability of CD8+ T cells to expand in the absence of PD-1 and LAG-3 
during the primary response of acute infection. We observed the cells in circulating blood 
from very early stages of clonal expansion to the start of the contraction phase. We report 
the kinetics of the CD8+ T cells in the absence of PD-1 and LAG-3 cells and whether the 
peak of the response varies from the wild type cells. By day 3 we were able to quantify 
CD8+ T cells in the circulating blood, consistent with previous reports that CD8+ clonal 
expansion starts at day 2 in the spleen.210 The peak of clonal expansion in response to 
VV-OVA is at day 5.210 Consistent with the kinetics of VV-OVA, in our studies the wild 
type group showed peak at day 5. We observed that in the absence of PD-1 and LAG-3 
CD8+ T cells initiate expansion earlier when compared to WT in the circulating blood. 
Additionally, they sustain an amplified response being at the peak of the response before 
and at the same time than WT cells do. Both groups contract at a similar time point. In 
conclusion the absence of both inhibitory receptors results in a steep and wide kinetic 
curve when compared to the WT counterpart.  (Fig. 3.1A, 3.2B). 
 
Once we confirmed that our cells expanded early after acute infection with VV-OVA, we 
tested the hypothesis that DKO cells have an enhanced expansion also in systemic and 
lymphatic organs. 
 
Consistent with past results and the negative regulatory role of the PD-1 pathway, the 
absence of PD-1 enhanced proliferation of CD8+ T cells. 211 The DKO cells also behaved 
as expected but in a tumor free environment, in a synergistic form with the absence of 
LAG-3 not affecting but enhancing clonal expansion. 129 In our model CD8+ T cells were 
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able to receive and process the needed signals to identify antigen, activate and expand. 
With these results we show that the absence of PD-1 and LAG-3 contributes to a greater 
clonal expansion of CD8+ T cells in a tumor free model during the acute phase of 
infection. We show that the absence of PD-1 and LAG-3 enhances CD8+ T cell 
expansion since early points after acute infection with VV-OVA.  
 
As expected after pathogenic stimulation the DKO cells were able to expand and generate 
clones. But not only were able to expand but did so in greater numbers when compared 

















Chapter IV: Effector function 
 
Section 4.1: Introduction 
 
Previous studies have reported that at the peak of clonal expansion two subsets of 
differentiated CD8+ T cells are distinguished: KLRG-1hi/CD127lo and KLRG-
1lo/CD127hi.94  T-bet directs the formation of KLRG-1hi/CD127lo effector CD8+ T cells, 
and KLRG-1 has been used as a marker of differentiation.94,212 Other studies show that 
the expression of KLRG-1 and the loss of TCF1 give rise to terminally differentiated 
effector T cells, a topic that we will discuss in depth in future chapters.43 
 
Additionally, evidence supports that T-bet and Eomesodermin (Eomes) are highly 
important in the formation of optimal performance of effector and memory CD8+ T 
cells.179 During the priming phase, T-bet and Eomes induce expression of IFN-, 
granzyme B, perforin, CXCR3 and CXCR4.179 In the absence of both T-bet and Eomes 
there is aberrant production of IL-17 that results in excessive infiltration of neutrophils 
and lethal inflammatory syndrome.213  
 
T-bet has also been linked to the regulation of expression of effector functions while 
Eomes is involved in directing the expression of proteins to maintain the T cell memory 
pool.94,106,107,214 It is important to mention too that the stability, functionality and 
differentiation of CD8+ T cells seems in part to be commanded by the expression ratio 
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between T-bet or Eomes.179 Wherry and colleagues have reported that when cells with an 
























Section 4.2: Results 
 
To determine the role of inhibitory receptors in CD8+ T cell memory formation, we used 
an OT-I PD-1 KO/LAG-3 KO mouse model. As we reported in chapter III, at day 8 (p.i.), 
single knockout (PD-1 KO or LAG-3 KO) as well as DKO OT-I cells showed greater 
clonal expansion compared to wild type (WT) (Fig.4.2 B-E). Additionally to enhanced 
expansion we identified two subsets of CD8+ T cells previously reported.216 We found 
that KLRG-1hi/CD127lo expression is increased in DKO CD8+ T cells. A larger 
percentage of DKO CD8+ T cells were KLRG1hi/CD127lo compared to WT or single KO 
cells (Fig. 4.1C), suggesting that DKO T cells have an increased percent of differentiated 



















































Figure 4.1 PD-1/LAG-3 absence influences CD8+ T cell activation in the acute phase 
of infection. (A-D) Percent of CD127 and KLRG expression by transferred OT-I cells at 
day 8 p.i. N = 5 mice / group. Experiments were repeated twice. *p<0.05. **p<0.001, 





















Previous studies have shown that Eomes helps memory cells with long-term persistence, 
competitive fitness and secondary expansion after re-challenge, but is not a promoter of 
memory-precursor fate107. Thus, we tested the hypothesis that DKO CD8+ T cells’ 
inability to expand would be due to aberrant expression of Eomes during the acute 
response. To test this, we assessed the expression of the transcription factors T-bet and 
Eomes in the spleen. Our data show that wild type and single knock out CD8+ T cells had 
less expression of Eomes when compared to the DKO (Figs 4.2A). Additionally, the 




































Figure 4.2 PD-1/LAG-3 absence influences CD8++ T cell activation in the acute 
phase of infection. (A) Percent of Eomes and T-bet by transferred OT-I cells at day 8 p.i. 
N = 5 mice / group. Experiments were repeated twice. *p<0.05. **p<0.001, Kruskal-






















Section 4.3: Discussion 
 
Naïve CD8+ T cells have high expression of CD127. Expression of CD127 is lost rapidly 
after encounter with pathogen. CD8+ T cells responding to antigen downregulate CD127.  
During a VV-OVA infection CD127 is significantly down-regulated on day 5 and returns 
to naïve levels by day 7. In our studies we see this behavior in all our groups, however 
the expression of CD127 is higher in the wild type cells when compared with the other 
groups.  
 
During the primary response the absence of both checkpoints did not impact activation as 
shown by the expression of KLRG-1. DKO cells expressed a greater percent of KLRG-1 
when compared to the wild type. However, DKO cells retained expression of both 
markers CD127 and KLRG-1 in almost an equal percent. Previous studies have reported 
that without the expression of TCF1, CD8+ T cells differentiate into effector cells 
identified by the expression of KLRG-1. And consistent with those studies we identified 
KLRG-1hi/CD127lo expression is increased in DKO T cells. 
 
In terms of clonal expansion, the DKO cells had a greater percent as well as absolute 







Chapter V: Cytokines 
 
Section 5.1: Introduction 
 
A plethora of tightly regulated events activates antigen-specific CD8+ T cells responding 
to infection. This results in their rapid expansion and differentiation into effector cells 
whose ultimate goal is to help clear infection.94 During an infection, T cell proliferation 
and differentiation is modulated a co-stimulatory signals that among other things, help to 
stimulate the production of cytokines.179 The main pro-inflammatory cytokines produced 
during a viral infection are type I IFNs, IFN, IL-2, IL-12, IL27 and IL 33 that contribute 
to proliferation, differentiation and survival of activated CD8+ T cells.179 
 
Many factors influence a robust immune response during infection. Although we focus 
on the importance of PD-1 and LAG-3 for the priming phase of CD8+ T cell, we cannot 
isolate or undermine the importance of other factors of cytokine production. Past studies 
have reported that IL-2 signaling during the primary response to infection, primes the 
formation of competent CD8+ memory T cells that can generate robust secondary 
responses.217 
 
In our studies we used Vaccinia-ova; virus-specific CD8+ T cells control pathogen 
invasion through the direct killing or virus-infected cells.218 Past studies have 
demonstrated that CD8+ T cells responding to viruses have heterogenous effector 




Several studies have proven that in the absence of PD-1 signaling CD8+ T cell function is 
improved, including cytotoxicity, proliferation and cytokine production.159,220 Similar 
results have been reported for LAG-3.89,126,167,169 But of more relevance to our study, the 
absence of PD-1 and LAG-3 have a synergic effect in CD8+ T cell effector 
function.129,165,221 
 
Here we show that a tumor free mouse CD8+ T cell response shows an expected immune 

















Section 5.2: Results 
 
DKO CD8+ T cells have increased polyfunctionality during the acute phase of infection. 
 
Previous experiments using murine tumor models have shown that in the absence of PD-
1 and LAG-3, CD8+ T cells increase in number and effector function.129,165 We next 
sought to test the hypothesis that in a murine tumor-free model the absence of PD-1 and 
LAG-3 influences cell effector function.  At day 8 p.i. with VV-OVA, DKO OT-I cells 
showed increased production of cytokines (IFN, IL-2) compared to WT or single KO 
CD8+ T cells (Fig. 5.1A-F). The ability to clear pathogen was also enhanced in the double 
KO cells (Fig 5.1G). The absence of PD-1 and LAG-3 thus seems to increase terminal 


















































































































Figure 5.1 DKO OT-I cells have augmented effector function in the acute phase. (A) 
Schematic representation of organ collection. (B-E) Cytokine expression by WT, PD-1 
KO, LAG-3 KO and DKO CD8+ T cells isolated from spleens on day 8 p.i.  (F) 
Schematic representation of pathogen burden assessment. (G) Pathogen clearance in the 
liver determined by CFU number. N = 5 mice / group. Quantification of LM-OVA CFU 
in the livers of recipient mice at day 8 p.i. following transfer of OT-1 cells. Experiments 
were repeated twice. Error bars denote +/- SEM. *p<0.05. **p<0.001, Kruskal-Wallis 


















Section 5.3: Discussion 
 
The CD8+ T cell response to pathogens is crucial to clear infection.  A major function of 
CD8+ T cells responding to infection is the lysis of virus-infected cells. A robust and 
effective response to infection is measured by the production of cytokines including 
TNF-, IFN- and IL-2.  
 
Consistent with previous studies,129 our results show that effector function, by the 
increased expression of cytokines, is enhanced in DKO T cells compared to WT T cells, 
but extend this finding to a murine model of acute infection. CD8+ T cells seem to behave 
as expected under a viral infection, not only migrating to different organs but also 
effectively producing cytokines. We observe that the production of cytokines is 
homogenous throughout all organs. 
 
We can assess that in the absence of PD-1 and LAG-3, CD8+ T cells have enhanced 
efficiency clearing a pathogen. We can conclude that during the primary acute response 
to infection in the absence of PD-1 and LAG-3, antigen-specific CD8+ T cells have 
























Chapter VI: Memory 
 
Section 6.1: Introduction 
  
The concept of immunological memory has been one of the most controversial and 
disagreed upon.15,16,56 However there is a consensus in the importance of the immune 
memory222  and in the importance of understanding how it is generated and maintained so 
as to manipulate it for therapeutic benefits.74,223,224  We know that immunological 
memory confers to the immune system the ability to remember a response to a specific 
antigen and upon reencounter, it reacts faster and greater to the same antigen.93 A key 
player of the immune system is the CD8+ T cell, especially for combating intracellular 
pathogens and cancer.180,225 As mentioned in chapter one, a primary goal of CD8+ T cells 
in response to infection is the generation of a  large number of clones and a second one is 
the generation of long lasting immunological memory. 179 On the other hand, CD8+ T cell 
memory has itself two major phenotypes: rapid increase of clone numbers (faster than the 
first response) and rapid elaboration of effector functions (cytotoxicity and cytokine 
production).30  
 
But before CD8+ T cells have the capacity to behave as memory cells, they must pass 
through a synchronized and chronological series of steps.226  A naïve CD8+ T cell 
circulating in  the body can be activated once it encounters and recognizes an antigen. 
This encounter needs to take place in the context of MHC I antigen presentation, co-
stimulation through immune checkpoints and stimulation through receptors for 
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cytokines.70,227  The CD8+ T cell memory repertoire is diverse, heterogenous and 
phenotypic and functional different. Therefore to use a single property to identify or 
conceptualize memory CD8+ T cells is not only unfair but would give a narrowing 
perspective.228 Thus, it results challenging to adhere to a single phenotype or marker as 
exclusive criteria for a CD8+ T cell that has become a memory cell. 179 
 
In the same way it would be too narrowing to use a single phenotypic distinction on how 
precursors of  CD8+ T cell memory are formed.194,229–231  However, some studies have 
reported the importance of the early stages of CD8+ T cell activation for determining the 
fate of cells that respond to infection90 Other studies along the same lines point to the fact 
that CD8+ T cell memory programming occurs in a short period of time and in a very 
early stage of activation.35,202,232 
 
The success of cancer immunotherapy is measured though several parameters; one of 
those is the generation of protective immunity. A key way to prevent relapse metastases 
and recurrence is the formation of immune memory against the primary tumor. 233 
 
As with VV-OVA, infection with Listeria monocytogenes, elicits an expected CD8+ T 
cell kinetic response: expansion, contraction and memory development.208,234 We used an 
attenuated version that results in an expansion peak at its maximum at day 7.235,236 
Infection with Listeria monocytogenes follows a common pattern as any acute infection 
and after reaching a peak of expansion, it begins to contract and 5 to 10% of the CD8+ T 
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cell clones at the peak transition to memory.237  However during the recall responses the 
























Section 6.2: Results 
 
Absence of PD-1 and LAG-3 drives terminal differentiation at the expense of self-
renewal. 
After assessing the behavior of the CD8+ T cells in the acute phase of infection, we 
wondered about the quality of memory cells they could produce. We hypothesized that loss 
of PD-1 and LAG-3 would also generate an enhanced response to secondary challenge in 
the setting of a non-chronic infection (Fig. 6.3A). Unexpectedly, when we examined the 
response of DKO T cells to re-challenge with cognate antigen, we found that DKO T cells 
failed to expand (Fig. 6.1B). To confirm the presence of CD8+ T cells after the expansion 
plateau, we repeated our experimental setup, let the infection clear and assessed the 
presence of CD8+ T cells on day 21 after primary infection (Fig.6.1C). At day 21 after the 
first infection, the frequency of CD8+ T cells was not statistically different when comparing 
all groups. The observed difference in clonal expansion during the first days of the infection 















































Figure 6.1 DKO OT-I cells fail to expand in response to secondary infection. (A) 
Summary of in vivo secondary infection model. OT-I CD8+ T cells of the indicated 
genotypes are adoptively transferred to congenic mice on day 0, followed by infection 
with VV-OVA on day 1. Sixty days later, the mice are re-infected with Listeria-ova and 
the organs are collected at day 64. (B) Representative FACS plots of WT, PD-1 KO, 
LAG-3 KO and DKO T cells isolated from spleens at day 4 post-re-challenge. 
Percentages of clonotypic T cells obtained from spleens. (C) Schematic representation of 
assessment of presence of cells at day 21. (D) Representative plots of CD8+ T cells 
isolated from the spleen on day 21 and their respective percentages of clonotypic 
expansion. N = 5 mice / group. Experiments were repeated twice. * p<0.05. **p<0.001. 

































Blockade of PD-1 and LAG-3 increases TCF1 silencing.  
Silencing of TCF1 drives terminal CD8+ T cell differentiation and loss of self-renewal, a 
requisite for memory formation.44,106,239 (Fig 6.2) To investigate the mechanism 
underlying loss of secondary recall responses in the absence of PD-1 and LAG-3, we 
asked whether TCF1 expression was affected during the acute response. Mice were given 
either no treatment or combined αPD-1/αLAG-3 blockade a day before adoptively 
transferring cells and infecting them with VV-OVA (Fig. 6.3A). At day 4 p.i., when 
TCF1hi progenitors self-renew and give rise to differentiated TCF1lo effector cells43, we 
found that combined PD-1/ LAG-3 blockade resulted in over-differentiation of TCF1lo 
cells, with correspondingly increased expression of the activation marker CD44 and 
effector cell transcription factor IRF4 (Fig 6.3B). We then performed in 
vitro differentiation experiments with antibody-mediated PD-1/LAG-3 blockade in OT-I 
and P14 T cells (Fig 6.3C). T cells receiving αPD-1 and αLAG-3 treatment had decreased 

























Fig 6.2 Schematic representation of TCF1 silencing and memory formation. TCF1 is 
a transcription factor that is key in regulating T cell memory. TCF1 marks and maintains 
CD8
+
 T cells with capacity for self-renewal in acute and chronic infections.TCF1
lo
 cells 
only give rise to more TCF
lo
 cells acutely, and lack self-renewal properties after pathogen 
clearance. In the other hand TCF1
hi 
have the capacity of producing TCF1
lo
 cells while 
self-renewing the TCF1
hi
 pool. Once pathogen is cleared, the TCF1
hi
 cells have self-
renewal properties and remind quiescent. Thus, entering the central memory T cell pool. 
In other words, as reported by the Reiner lab, silencing expression of TCF1 marks loss of 






















































































Figure 6.3. Blockade of PD-1 and LAG-3 increases TCF1 silencing. (A) Schematic representation 
of in vivo checkpoint blockade. OT-I CD8+ T cells were adoptively transferred to congenic 
recipient mice on day 0, followed by infection on day 1 and PD-1/LAG-3 antibody blockade on 
day 1 and 3. Spleens were collected on day 4. (B) Left: TCF1 expression versus cell division for 
transferred OT-I cells. Middle: Quantification of percent TCF1lo cells. Right: CD44 and IRF4 
expression on transferred OT-I cells N = 5 mice / group. Experiments were repeated twice. (C) 
Schematic representation of in vitro checkpoint blockade. OT-I CD8+ T cells positively selected 
and plated with Ova peptide and PD-1/LAG-3 antibody blockade on day 1 and 3.  Cells were 
collected on day 4. (D) FACS plots and quantification of TCF1 lo of CD8+ treated with either 
Isotype, PD-1, LAG-3, or PD-1/LAG-3 antibody at day 4 of culture. OT-I (upper) or P14 
(lower). * p<0.05. ** p<0.01. *** p<0.001. n.s. not significant. Kruskal-Wallis test with Dunn’s 































Altering the metabolism of CD8+ T cells in the absence of PD-1 and LAG-3 changes the 
phenotype of TCF1.  
PD-1 blockade acts through CD28 signaling to enhance anti-tumor immunity,124,240 and 
CD28 induces PI3K activity as well as downstream anabolic pathways.241 A constellation 
of PI3K-driven and anabolic processes mediates repression of TCF1 during T cell 
differentiation.175 We hypothesized that scavenging anabolism-associated reactive 
oxygen species (ROS) or blocking class I PI3K signaling might blunt the over-
differentiation phenotype induced by combined PD-1/LAG-3 blockade (Fig. 6.4A). 
Indeed, perturbing these anabolic pathways in the context of combined PD-1/LAG-3 
























































 Figure 6.4. Perturbing ROS and PI3k rescues the expression of TCF1 in the 
absence of PD-1 and LAG-3 in CD8+ T cells. (A) Schematic representation of in vitro 
checkpoint blockade. OT-I CD8+ T cells positively selected and plated with on day 1 with OVA 
peptide, N-acetyl cysteine (ROS scavenger), or Pictilisib (Class I PI3K inhibitor) and PD-1/LAG-3 
antibody blockade on day 1 and 3.  Cells were collected on day 4. (B) ROS scavenging or 
inhibition of Class I PI3K activity rescues over-differentiation induced by checkpoint blockade. 
Left: P14 cells are treated with either no drug, N-acetyl cysteine (ROS scavenger), or Pictilisib 
(Class I PI3K inhibitor). Right: quantification of TCF1lo cell frequency at day 4 of culture. * p<0.05. 

















Section 6.3: Discussion  
 
As previously reported, TCF1 silencing determines the fate of T cells differentiation.43 
Consistent with those studies, we show that in the absence of PD-1 and LAG-3 there is a 
higher percentage of TCF1lo cells, which has been associated with terminal 
differentiation of CD8+ T cells.52  Additionally, other studies report that differentiating T 
cells show metabolic changes such as glycolysis and ROS production that are coupled to 
the silencing of TCF1 or to the manipulation of PD-1.175,242  We report that in the absence 
of PD-1 and LAG-3, CD8+ T cells failure to expand during the secondary response to 
acute infection phase. This might be due to the higher TCF1 silencing we observed 
during the early phases of T cell differentiation that take place following primary acute 
infection. 
 
We show that T cells fail to expand in response to re-challenge with acute infection using 
an OT-1 KO in vivo model, supporting our hypothesis that the immune checkpoints PD-1 
and LAG-3 influence CD8+ T cell differentiation.101 We moved our studies in vitro to 
examine the mechanism of how this happens. We report that blocking PD-1 and LAG-3 
silences the expression of TCF1, and CD8+ T cells show greater potential to differentiate 
into effector cells at the expense of self-renewal and memory formation in murine OT-1 
and P14 cells. It would be valuable to assess TCF1 expression and its influence in long-





Our results suggest that loss of PD-1 and LAG-3 in CD8+ T cells results in greater 
effector differentiation at the expense of long-term T cell memory formation due to 
increased silencing of TCF1. In chronic-active states, such as cancer, greater effector 
differentiation could occur at the expense of self-renewal of the active progenitors that 
continually give rise to new effector cells. After acute infection, cells activated without 
immune checkpoints might fail to expand during re-challenge, possibly due to enhanced 



















Chapter VII: Discussion 
 
The present data show that the immune checkpoints PD-1 and LAG-3 influence CD8+ T 
cell differentiation. We show that in the absence of PD-1 and LAG-3, CD8+ T cells lead 
to increased T cell effector function during the acute response to infection. However, this 
does not lead to an enhanced secondary response. Rather than being enhanced, the 
secondary response is nonexistent as the double knockout cells seem unresponsive to re-
challenge (Fig 7.1).  Although during the primary response T cells responded effectively 
and were able to clear pathogen infection, they were not effective in generating long term 
memory. Analysis of T cells showed that in the absence of PD-1 and LAG-3, CD8+ T 
cells show greater potential to differentiate into effector cells at the expense of self-


















































Figure 7.1. Kinetics of memory CD8+ T cell.  T cell differentiation during an acute 
response in the absence of PD-1 and LAG-3. (A) Kinetic curve of T cell expansion 
during a viral infection in red in absence of PD-1 / LAG. (B) After pathogen encounter 



















As in previous research our results show enhanced T cell function in double knockout T 
cells, but in an acute infection mouse model. However, unlike reported results of single 
PD-1 knockout in a chronic model; in our model double knockout T cells neither produce 
cytokines nor behave as exhausted-like cells, and they also fail to expand upon re-
challenge. 129,211,243 As previously reported, TCF1 silencing determines the fate of T 
cells.176  We show that in the absence of PD-1 and LAG-3 there is higher percent of 
TCFlo T cells, which as reported by Wen-Hsuan52 leads to terminal differentiation.  
 
Additionally it has been reported that differentiating T cells show metabolic changes that 
are coupled to the silencing of TCF1 or to the manipulation of PD-1(Fig 7.2).160 This 
supports our findings that in the absence of PD-1 and LAG-3 T cells fail to expand due to 



























Figure 7.2. Metabolic changes coupled to the silencing of TCF1 in CD8+ T cell 
differentiation. Once T cells are activated, they increase in size and undergo deep 
metabolic changes. They transition from a quiescent state to a more active one, 
metabolically they transition from oxidative phosphorylation (OXPHOS) to glycolysis. 
Signals from growth factor cytokines like interleukin-2 (IL-2) and the ligation of 
costimulatory CD28 help activate glycolytic pathways by inducing the phosphoinositol 3-
kinase (PI3K)-dependent activation of AKT. Mamalian target of rapamycin (mTOR) is a 

















Studies show that for clonal expansion, CD8+ T cells do not need a stable interaction with 
dendritic cells, as a result CD8+ T cells differentiate into effector cells. However, if such 
interaction does not happen, memory cells are affected. This is a crucial observation for 
our model, since such findings support that the memory potential of CD8+ T cells can be 
programmed very early in the response phase, as early as the first 24 hours of priming.244  
 
Several recent findings suggest that restraining anabolic signals in parallel with 
checkpoint blockade can improve immunotherapeutic response for multiple cancers as 
well as augment tumor control following adoptive transfer therapy.148,241,245–247  
Moreover, construction of chimeric antigen receptor T cells with signaling domains that 
promote oxidative phosphorylation over aerobic glycolysis promotes more effective 
tumor eradication (Fig 7.3).248 Our results support future immunotherapy design that 
balances combinatorial checkpoint blockade therapies with treatments to restrain anabolic 
signaling and provide context for the seemingly paradoxical findings that combination 



























Figure 7.3. Metabolic changes coupled to the silencing of TCF1 in CD8+ T cells can 
be manipulated. We hypothesized that scavenging anabolism-associated reactive oxygen 
species (ROS) or blocking class I PI3K signaling might blunt the over-differentiation 
phenotype induced by combined PD-1/LAG-3 blockade. Therefore, we used pictilisib 

















These data are important in understanding the differentiation of CD8+ T cells during 
acute response in the context of immune checkpoints. Understanding how PD-1 and 
LAG-3 influence the formation of memory can help design combinatorial cancer 
therapies that focus on vaccines thus reducing the potential of tumor development in case 
of relapse. Here, we show how the combined absence of PD-1 and LAG-3 impacts 
immune responses in an acute infection and re-challenge model. We show that the 
combined loss of PD-1 and LAG-3 leads to defective memory cell formation and poor 
recall responses to secondary challenge. We then assess the mechanism underlying this 
deficit and characterize the role of TCF1 expression in regulating memory cell 
differentiation. There are several models proposed for the understanding of how CD8+ T 
cells arise. At first it was reported that some effector CD8+ T cells had the ability of 
either retaining or re-expressing IL-7R at the peak of the immune response. Those cells 
then survived the contraction phase and gave rise to memory cell population. We have 
used all those reports to do our studies to assess the ability of cells to get activated and 













- Prior findings in tumor models support that in our results T cell proliferation and 
effector cell differentiation is enhanced by the double deficiency of PD-1 and 
LAG-3 during acute infection.  
- Our results show that  in contrast to the phenotype of enhanced primary 
expansion, DKO T cells are impaired in secondary expansion. 
- The continued capacity for antigen-elicited proliferation and self-renewal 
alongside production of differentiated cells has been linked to persistent 
expression of TCF1 by CD8+ T cells.  
- Anabolic PI3K signaling causes FoxO1 inactivation and TCF1 silencing, while 
PD-1 signaling opposes anabolic PI3K/AKT/mTOR, the subsequent defect in 
expansion of DKO T cells may relate to an inability to maintain expression of 
TCF1 and the associated capacity for proliferation and self-renewal. 
- Whether PD-1/LAG-3 blockade is functioning through TCF1 silencing will 
require further investigation. 
- Emerging evidence suggests that control of acute, persistent, and chronic-active 
infections relies on stem- and progenitor-like T cells that have the paradoxical 
capacity to self-renew while producing more differentiated daughter cells 
- The role of inhibitory receptors in opposing costimulatory signals and anabolic 
metabolism suggests that inhibitory pathways may have evolved as an obligatory 
counterbalance for the dichotomous processes of immunity: anabolism and 
catabolism; differentiation and self-renewal; function and durability. 
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- Restraining anabolic signals in parallel with checkpoint blockade could improve 
immunotherapeutic response for multiple cancers as well as augment tumor 
control following adoptive transfer therapy 
- Our results support future immunotherapy design that balances combinatorial 
checkpoint blockade therapies with treatments to restrain anabolic signaling and 
provide context for the seemingly paradoxical findings that combination 
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